Prices are cooling off, as last week’s consumer price index reading revealed a 0.1% decrease on a monthly basis. However, the index has still gained 6.5% from the prior year. Investors responded positively to this news, with the three major indexes closing higher on Friday.
Navigating the uncertain investment landscape can be difficult, but to aid in the process, Stock Target Advisors, a platform that ranks analyst ratings based on their track records, has selected three stocks recommended by Wall Street’s top professionals.
Alphabet
Alphabet, the parent company of Google, is a leading technology company that is at the forefront of major trends in the industry. The company has a strong presence in multiple areas, including mobile engagement, online activities, digital advertising, and cloud computing. These areas are all growing and expanding, and Alphabet (NSD:GOOGL)is well-positioned to take advantage of these trends.
Additionally, Alphabet has a strong focus on artificial intelligence (AI). This is driving the development of better and more functional products, as the company is investing in AI-focused initiatives and efforts to achieve cost and operating efficiencies. These efforts are expected to continue driving the company’s growth in the future.
Recently, Tigress Financial Partners analyst Ivan Feinseth reiterated a buy rating on the stock. Feinseth is bullish on the stock due to the robust trends in cloud and search, which he believes “continue to highlight the resiliency of its core business lines.” He also believes that any weakness in the stock’s near-term performance is a buying opportunity for investors and get venture capitalist India.
Feinseth is also positive about Alphabet’s financial health. He notes that the company has a strong balance sheet and cash flow, which enable it to fund key growth initiatives, strategic acquisitions, and enhance shareholder returns through ongoing share repurchases. Feinseth is ranked No. 229 among more than 8,000 analysts on Stock Target Advisor, and his ratings have a 60% profitability rate and have generated average returns of 11.1%.
Overall, Alphabet is a strong company with a solid presence in multiple growing areas of the technology industry. Its focus on AI is driving product improvements and cost efficiencies, and the company has a strong financial position to fund growth initiatives and enhance shareholder returns. This has led to a positive outlook from analysts, with Feinseth recently reiterating a buy rating on the stock.
OrthoPediatrics Corp.
OrthoPediatrics, also known as KIDS, is a medical equipment company that specializes in designing, manufacturing and distributing products for treating orthopedic conditions in children. Orthopedics is a branch of medicine that deals with the diagnosis, treatment, and prevention of disorders and injuries of the musculoskeletal system. This includes bones, joints, muscles, tendons, ligaments, and other related structures.
KIDS operates globally in over 35 countries, and it has a strong presence in the pediatric orthopedic market. The pediatric orthopedic market is a niche market that is relatively underserved, and this has worked to the company’s advantage. KIDS has a dominant market share in this market, giving it a competitive edge in the medical equipment industry. The company’s products are used in the treatment of orthopedic conditions in children, such as scoliosis, spinal deformities, and fractures.
Recently, Ryan Zimmerman, a BTIG analyst, has reiterated his buy rating and $62 price target on KIDS stock. Zimmerman cites the significant market opportunity and the company’s leading brand among pediatric orthopedic surgeons, as well as its concentrated customer base, as reasons for the stock’s potential growth. He notes that the pediatric orthopedic market is relatively underserved and larger players in the medical equipment industry have mostly overlooked this opportunity. KIDS, with its dominance in this market, stands to benefit from this space.
Zimmerman is a well-known analyst in the financial industry and has a 660th ranking among over 8,000 analysts tracked on Stock Target Advisor. Furthermore, 47% of his ratings have been successful, generating 9% average returns per rating. This means that his track record of making accurate stock predictions is relatively strong and investors may want to take his recommendations into consideration when making investment decisions.
Intuitive Surgical
Medical technology company Intuitive Surgical (NSD:ISRG) specializes in developing and manufacturing robotic-assisted, minimally invasive surgical devices. The company’s products are designed to improve the accuracy and efficiency of surgical procedures, and it is considered a pioneer in the field of robotic surgery.
Recently, Intuitive Surgical announced preliminary results for the fourth quarter of 2022 (4Q22), as well as growth guidance for procedures in the upcoming fiscal year (FY23). These results were in line with the expectations of analyst Zimmerman, who follows the company closely.
Based on these results, Zimmerman reiterated his bullish stance on the company with a buy rating and a $316 price target. In his analysis, he cites several reasons for his bullishness. First, he believes that there are headwinds entering FY23, but that ISRG is well-positioned to continue seeing improving market dynamics. He also notes that there is potential for the launch of a next-generation system, which could drive additional growth for the company.
Zimmerman also believes that ISRG has long-term growth potential in the area of robotic surgery. He sees the company as a “clear leader in the space” and notes that the pandemic has increased the importance of computer-aided surgery, due to the accurate clinical outcomes it can provide. He expects that this will drive the adoption of Intuitive Surgical’s products over time, further fueling the company’s growth.
Overall, Zimmerman’s analysis suggests that Intuitive Surgical is well-positioned for continued growth in the robotic surgery market, and that the company’s recent results and growth guidance support this view. He suggests buying the stock on current weakness, as he believes that the company’s long-term potential outweighs any short-term headwinds.
Read Also : Scope of Macroeconomics